1. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. (19th September 2020) Authors: Juarez, Maria; Diaz, Nieves; Johnston, Geoffrey I; Nayar, Saba; Payne, Andrew; Helmer, Eric; Cain, Dionne; Williams, Paulette; Devauchelle-Pensec, Valerie; Fisher, Benjamin A; Giacomelli, Roberto; Gottenberg, Jacques-Eric; Guggino, Giuliana; Kvarnström, Marika; Mariette, Xavier; Ng, Wan Fai; Rosa... Journal: Rheumatology Issue: Volume 60:Number 3(2021) Page Start: 1364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). (June 2019) Authors: Juarez, Maria; Diaz, Nieves; Johnston, Geoffrey I.; Nayar, Saba; Payne, Andrew; Helmer, Eric; Cain, Dionne; Williams, Paulette; Ng, Wan Fai; Fisher, Benjamin; Gottenberg, Jacques-Eric; Guggino, Giuliana; Mariette, Xavier; Kvarnström, Marika; Devauchelle-Pensec, Valerie; Rosas, Jose; Sanchez-Burso... Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1692 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗